Answering Challenges in the Use of Immediate Use Steam Sterilization


Healthcare has plenty of potential pain points to go around, but one of the industry’s longest lasting is the proper use of immediate use steam sterilization, or IUSS.

The procedure, traditionally known as “flash sterilization,” offers the quickest possible time between an instrument’s use and its ability to be used again. However, that benefit is countered by several key challenges.

Notably, a lack of documentation and proper recordkeeping, specifically around the use of trays, and general concern about the efficacy of IUSS have led the AAMI to support minimal use of the practice, if it’s used at all.

However, IUSS does present some benefits. Medical professionals still like it in specific scenarios for its ability to keep tools available, offset supply drops or late arrival, and avoid contamination in the middle of a procedure.

So, if it’s to be used at all, how can the industry ensure it’s being done in as safe a way as possible? Enter Censis Technologies.

On this Censis Technologies podcast, Kelly Swails (MAOL, CRCST, CHL, CIS, CER, ST), Senior Clinical Educator for Censis, joined host Daniel Litwin to break down how the company’s CensiTrac solution can give medical professionals holistic insight into their processes and help them make the right decisions for each unique scenario.


Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook –
LinkedIn –

Follow us on social media for the latest updates in B2B!


NRF 2022 Retail's Big Show
What’s in the Shopping Cart for the 2022 National Retail Federation’s Big Show?
January 14, 2022
 In just a few short days, from January 16th through the 18th, the National Retail Federation will launch Retail’s Big Show in the shopping capital of the world, New York City. As retail Read more
Schools Struggle to Reach Their Education Technology Goals. Here’s Why and How To Fix It.
January 14, 2022
As we hit the two-year mark of the COVID-19 pandemic, the education sector continues to struggle in adjusting to virtual and hybrid education at scale. In 2020, McKinsey estimated that, due to COVID Read more
85% of Clinical Drug Trials Face Delays. What's the True Cost?
85% of Clinical Drug Trials Face Delays. What’s the True Cost?
January 14, 2022
  Clinical trials can save lives and provide new ways to treat disease. The industry estimates that 85% of all clinical trials face delays due to patient enrollment. Understanding that challenge Read more